The European Union has banned the marketing of around 700 generic medicines for alleged manipulation of clinical trials conducted by India’s pharmaceutical research company GVK Biosciences.
Expressing disappointment and concern over the EU banning sale of around 700 pharma products clinically tested by GVK Biosciences, India has deferred the talks with the European Union on the proposed free trade agreement.
Chief negotiators of India and the EU were scheduled to resume the negotiations on the Broadbased Investment and Trade Agreement (BTIA) this month.
“Government of India has taken a decision to defer the proposed talks between the Chief negotiators on BTIA for the present. Details